JP2004515460A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004515460A5 JP2004515460A5 JP2001585747A JP2001585747A JP2004515460A5 JP 2004515460 A5 JP2004515460 A5 JP 2004515460A5 JP 2001585747 A JP2001585747 A JP 2001585747A JP 2001585747 A JP2001585747 A JP 2001585747A JP 2004515460 A5 JP2004515460 A5 JP 2004515460A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- mmp
- retinoid
- thirteen
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 description 23
- 239000000203 mixture Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 206010000496 acne Diseases 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 208000002874 Acne Vulgaris Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 239000003602 elastase inhibitor Substances 0.000 description 4
- 239000003862 glucocorticoid Substances 0.000 description 4
- 150000004492 retinoid derivatives Chemical class 0.000 description 4
- 229940122858 Elastase inhibitor Drugs 0.000 description 3
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 3
- 102100023118 Transcription factor JunD Human genes 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- FAWLNURBQMTKEB-URDPEVQOSA-N 213546-53-3 Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(O)=O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(C)C FAWLNURBQMTKEB-URDPEVQOSA-N 0.000 description 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 229940125970 Toll-Like Receptor inhibitor Drugs 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical group C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 102000036444 extracellular matrix enzymes Human genes 0.000 description 1
- 108091007167 extracellular matrix enzymes Proteins 0.000 description 1
- 239000003591 leukocyte elastase inhibitor Substances 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57659700A | 2000-05-22 | 2000-05-22 | |
| US09/852,154 US20040235950A1 (en) | 1999-05-20 | 2001-05-09 | Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes |
| PCT/US2001/016537 WO2001089502A2 (en) | 2000-05-22 | 2001-05-22 | Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004515460A JP2004515460A (ja) | 2004-05-27 |
| JP2004515460A5 true JP2004515460A5 (enExample) | 2008-07-10 |
Family
ID=27076996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001585747A Pending JP2004515460A (ja) | 2000-05-22 | 2001-05-22 | ざ瘡によって誘発される炎症および真皮マトリックス分解酵素に対して用いる組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20040235950A1 (enExample) |
| EP (1) | EP1284721A2 (enExample) |
| JP (1) | JP2004515460A (enExample) |
| AU (1) | AU2001271266A1 (enExample) |
| CA (1) | CA2409929A1 (enExample) |
| MX (1) | MXPA02011431A (enExample) |
| WO (1) | WO2001089502A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050033251A1 (en) * | 1998-12-08 | 2005-02-10 | Quick-Med Technologies, Inc. | Controlled release of biologically active substances from select substrates |
| DE10127432A1 (de) * | 2001-06-06 | 2002-12-12 | Beiersdorf Ag | Wirkstoffkombination zur Verhinderung unerwünschter Hautpigmentierung |
| US20100222316A1 (en) * | 2004-04-29 | 2010-09-02 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| EP1971868A2 (en) * | 2006-01-05 | 2008-09-24 | Galderma Research & Development, S.N.C. | Acne lesions biomarkers and modulators thereof |
| US20080025930A1 (en) * | 2006-07-31 | 2008-01-31 | Hugo Corstjens | Anti-aging Compositions Comprising Menyanthes Trifoliata Leaf Extracts and Methods of Use Thereof |
| AU2007299562A1 (en) * | 2006-09-19 | 2008-03-27 | Phylogica Limited | Neuroprotective peptide inhibitors of AP-1 signaling and uses therefor |
| WO2008053199A1 (en) * | 2006-10-30 | 2008-05-08 | Astrazeneca Ab | Combination therapy for the treatment of respiratory diseases |
| EP2276455A2 (fr) * | 2008-04-22 | 2011-01-26 | Centre National de la Recherche Scientifique | Utilisation d'inhibiteurs de kif13a et d'ap-1 pour inhiber la mélanogénèse |
| US10179900B2 (en) * | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
| BR112012004834A2 (pt) * | 2009-09-02 | 2018-03-13 | Univ Virginia Patent Foundation | acompanhar a probabilidade de hipoglicemia iminente em diabetes de dados de automonitiração de glicose no sangue (smbg) |
| US8895628B2 (en) * | 2010-10-25 | 2014-11-25 | Johnson & Johnson Consumer Companies, Inc. | Compositions comprising a retinoid and an NFkB-inhibitor and their methods of use |
| US20140086859A1 (en) | 2012-09-24 | 2014-03-27 | Johnson & Johnson Consumer Companies, Inc. | Low oil compositions comprising a 4-substituted resorcinol and a high carbon chain ester |
| RU2015156254A (ru) * | 2014-05-07 | 2017-07-04 | Конинклейке Филипс Н.В. | Устройство, система и способ выделения физиологической информации |
| US10058542B1 (en) | 2014-09-12 | 2018-08-28 | Thioredoxin Systems Ab | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith |
| KR20200063798A (ko) * | 2018-11-28 | 2020-06-05 | 박정혜 | 퀘르세틴, 제니스테인 및 알파리포산을 함유하는 여드름 피부 개선용 조성물 |
| WO2023068233A1 (ja) * | 2021-10-18 | 2023-04-27 | マルホ株式会社 | 活性阻害及び／又は産生抑制剤 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4005198A (en) * | 1975-09-12 | 1977-01-25 | Robert H. Van Aman | Treatment of acne vulgaris |
| US4219548A (en) * | 1978-09-01 | 1980-08-26 | The Procter & Gamble Company | Topical anti-inflammatory composition |
| US4942031A (en) * | 1988-02-23 | 1990-07-17 | Levin Robert H | Compositions containing LYCD and other topically active medicinal ingredients |
| LU87410A1 (fr) * | 1988-12-20 | 1990-07-10 | Cird | Composition cosmetique ou pharmaceutique contenant des microspheres de polymeres ou de corps gras chargees d'au moins un produit actif |
| JPH07501540A (ja) * | 1991-11-25 | 1995-02-16 | リチャードソン、ビックス、インコーポレーテッド | 皮膚シワ及び／又は皮膚萎縮を調節するための組成物 |
| DE4218572A1 (de) * | 1992-06-05 | 1993-12-09 | Asta Medica Ag | Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E |
| US5460620A (en) * | 1992-07-31 | 1995-10-24 | Creative Products Resource, Inc. | Method of applying in-tandem applicator pads for transdermal delivery of a therapeutic agent |
| FR2694934B1 (fr) * | 1992-08-24 | 1994-11-10 | Oreal | Composition pour le traitement de l'acné contenant un dérivé d'acide salicylique et dérivés d'acide salicylique. |
| CA2160139A1 (en) * | 1993-04-07 | 1994-10-13 | Richard Edward Galardy | Synthetic matrix metalloprotease inhibitors and uses thereof |
| FR2715565B1 (fr) * | 1994-01-31 | 1996-03-15 | Oreal | Composition cosmétique ou dermatologique stabilisée contenant plusieurs précurseurs d'un même actif pour maximaliser sa libération, son utilisation. |
| GB9405076D0 (en) * | 1994-03-16 | 1994-04-27 | Inst Of Ophtalmology | A medical use of matrix metalloproteinase inhibitors |
| CN1107495C (zh) * | 1994-07-01 | 2003-05-07 | 纺织研究院公司 | 去屑组合物 |
| US5445823A (en) * | 1994-10-20 | 1995-08-29 | The Procter & Gamble Company | Dermatological compositions and method of treatment of skin lesions therewith |
| DE4444238A1 (de) * | 1994-12-13 | 1996-06-20 | Beiersdorf Ag | Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden |
| US5652227A (en) * | 1995-01-30 | 1997-07-29 | Teronen; Olli Pekka | Inhibition of the degradation of connective tissue matrix protein components in mammals |
| US5643623A (en) * | 1995-06-07 | 1997-07-01 | Mars Incorporated | Health food product and its uses |
| US6218128B1 (en) * | 1997-09-12 | 2001-04-17 | Allergan Sales, Inc. | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities |
| US5837224A (en) * | 1996-01-19 | 1998-11-17 | The Regents Of The University Of Michigan | Method of inhibiting photoaging of skin |
| US5741896A (en) * | 1996-06-21 | 1998-04-21 | Allergan | O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
| DE19632840A1 (de) * | 1996-08-14 | 1998-02-19 | Landsberger Albert | Vitamin A-haltige Zusammensetzung |
| US5665367A (en) * | 1996-09-27 | 1997-09-09 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Skin care compositions containing naringenin and/or quercetin and a retinoid |
| US5739338A (en) * | 1996-11-05 | 1998-04-14 | Allergan | N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity |
| US5728846A (en) * | 1996-12-12 | 1998-03-17 | Allergan | Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives |
| US5804594A (en) * | 1997-01-22 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for improving wrinkles and other skin conditions |
| US5962030A (en) * | 1997-03-07 | 1999-10-05 | Akesis Pharmaceuticals, Inc. | Dietary supplement and method of treatment for diabetic control |
| AU7294098A (en) * | 1997-05-09 | 1998-11-27 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| TWI234467B (en) * | 1997-06-04 | 2005-06-21 | Univ Michigan | Composition for inhibiting photoaging of skin |
| WO1999009982A1 (en) * | 1997-08-25 | 1999-03-04 | Harold Brem | Prevention of adhesions and excessive scar formation using angiogenesis inhibitors |
-
2001
- 2001-05-09 US US09/852,154 patent/US20040235950A1/en not_active Abandoned
- 2001-05-22 MX MXPA02011431A patent/MXPA02011431A/es not_active Application Discontinuation
- 2001-05-22 WO PCT/US2001/016537 patent/WO2001089502A2/en not_active Ceased
- 2001-05-22 JP JP2001585747A patent/JP2004515460A/ja active Pending
- 2001-05-22 EP EP01950247A patent/EP1284721A2/en not_active Withdrawn
- 2001-05-22 CA CA002409929A patent/CA2409929A1/en not_active Abandoned
- 2001-05-22 AU AU2001271266A patent/AU2001271266A1/en not_active Abandoned
-
2005
- 2005-06-27 US US11/168,017 patent/US20060009494A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004515460A5 (enExample) | ||
| CA2600384C (en) | Compositions and methods for treating acne | |
| WO2002067988A3 (en) | Use of natural egfr inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth receptor | |
| AU2002233288A1 (en) | Combined use of Enzyme Inhibitors and Pharmaceutical Preparations thereof for the Treatment and Prophylaxis of Arteriosclerosis, for the Treatment and Prevention of Allergic Reactions of Type I According to the Gell and Coombs Classification, and for the Treatment and Prevention of Dermatological Diseases Associated with FO | |
| PT1227820E (pt) | Acidos oligossacarido-aldonicos e sua utilizacao topica | |
| MXPA04000654A (es) | Terapia dermica usando derivados de fosfato de agente de transferencia de electrones. | |
| DE602005007711D1 (de) | Hautpflegemittel die salicylsäure enthalten | |
| ATE361082T1 (de) | Pharmazeutische zusammensetzung aus komplexen kohlenhydraten deren anwendung | |
| EP1444984B1 (en) | Topical pharmaceutical compositions containing natural active constituents suitable for the prevention and treatment of mucosal inflammation processes | |
| WO2001028491A3 (en) | Method and composition for the treatment of dermatologic diseases | |
| PL370795A1 (en) | Composition based on etyllinoleate and triethylcitrate for the treatment of seborrhea and acne | |
| ECSP055820A (es) | Unidad para dosificación diaria de melatonina | |
| RU2007118663A (ru) | Способ применения адапалена при поддерживающей терапии угревой сыпи | |
| EP1383540A4 (en) | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR Wounds Healing | |
| ES2127613T3 (es) | Utilizacion de un antagonista de tnf-alfa para el tratamiento de rojeces cutaneas de origen neurogeno. | |
| WO2004100893A3 (en) | Methods for treatment of inflammatory diseases using ct-3 or analogs thereof | |
| DE60229235D1 (de) | D kupfersulfaten und sucralphat | |
| AU2002227052A1 (en) | Treatments for neurogenetic disorders, impulse control disorders, and wound healing | |
| CA2494473A1 (en) | Stabilized protein compositions for topical administration and methods of making same | |
| MXPA03011622A (es) | Uso de glicoproteina para el tratamiento y re-epitelizacion de heridas. | |
| US10071052B2 (en) | Method for the prevention and treatment of acne | |
| JPH08505402A (ja) | 粘膜表皮性及び表皮性の痛み、炎症及び感染症の治療方法及び治療用組成物 | |
| GEP20043231B (en) | Resorcinol Composition | |
| DE60228687D1 (de) | Cyanoacrylat-zusammensetzungen für die therapeutische behandlungvon wunden, die eine revision erfordern | |
| WO2003007909A3 (de) | Kosmetische oder dermatologische zubereitungen mit langanhaltender kühlender wirkung |